TY - JOUR
T1 - Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia
AU - Schilling, Paul J.
AU - Kurzrock, Razelle
AU - Kantarjian, Hagop
AU - Gutterman, Jordan U.
AU - Talpaz, Moshe
PY - 1991/10/1
Y1 - 1991/10/1
N2 - A 19‐year‐old man with Philadelphia‐positive chronic myelogenous leukemia treated with interferon‐alpha (IFN‐alpha) therapy for 45 months had systemic lupus erythematosus disease features: malar rash, migratory arthralgias, elevated antinuclear antibodies, elevated antinative DNA, hypocomplementemia, lymphopenia, and proteinuria. After discontinuation of the IFN and initiation of corticosteroids, there was gradual recovery of symptoms, a decline in antinative DNA and antinuclear antibodies to normal levels, and a decrease in proteinuria. The potential association between IFN therapy and the development of systemic lupus erythematosus, and the role of IFN in other autoimmune diseases, is discussed.
AB - A 19‐year‐old man with Philadelphia‐positive chronic myelogenous leukemia treated with interferon‐alpha (IFN‐alpha) therapy for 45 months had systemic lupus erythematosus disease features: malar rash, migratory arthralgias, elevated antinuclear antibodies, elevated antinative DNA, hypocomplementemia, lymphopenia, and proteinuria. After discontinuation of the IFN and initiation of corticosteroids, there was gradual recovery of symptoms, a decline in antinative DNA and antinuclear antibodies to normal levels, and a decrease in proteinuria. The potential association between IFN therapy and the development of systemic lupus erythematosus, and the role of IFN in other autoimmune diseases, is discussed.
UR - http://www.scopus.com/inward/record.url?scp=0026349435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026349435&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19911001)68:7<1536::AID-CNCR2820680713>3.0.CO;2-B
DO - 10.1002/1097-0142(19911001)68:7<1536::AID-CNCR2820680713>3.0.CO;2-B
M3 - Article
C2 - 1893353
AN - SCOPUS:0026349435
SN - 0008-543X
VL - 68
SP - 1536
EP - 1537
JO - Cancer
JF - Cancer
IS - 7
ER -